Availability of Streptomycin and Para-Aminosalicylic Acid --
United States
Since April 1992, CDC has distributed streptomycin to more
than 1000 patients with active tuberculosis under an
Investigational New Drug (IND) agreement until licensed, domestic
production of streptomycin could be reestablished in the United
States. In April 1993, the Food and Drug Administration issued a
license allowing Pfizer Inc. to produce and distribute
streptomycin. Beginning July 6, 1993, CDC will no longer accept new
requests from clinicians to place their patients on streptomycin.
Such requests should be directed to Richard Vastola, Roerig
Streptomycin Program, Pfizer Pharmaceuticals, Inc., 235 E. 42nd
Street, New York, NY 10017; telephone (800) 254-4445. CDC will
continue to resupply any patients enrolled in the IND protocol
before July 6, 1993, until they have completed their course of
streptomycin therapy. Until further notice, CDC will continue to
supply para-aminosalicylic acid under a separate IND agreement.
Additional information concerning streptomycin or
para-aminosalicylic acid is available from CDC's Drug Service,
Scientific Resources Program, National Center for Infectious
Diseases, telephone (404) 639-3670.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
